Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$550.72 USD

550.72
463,800

+3.25 (0.59%)

Updated Aug 27, 2024 04:00 PM ET

After-Market: $551.01 +0.29 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results

by Zacks Equity Research

BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2020 result driven mainly by da Vinci procedure volume growth.

Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues

by Zacks Equity Research

Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues

by Zacks Equity Research

DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues

by Zacks Equity Research

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

Sweta Killa headshot

4 Sector ETFs & Stocks to Bet on Q4 Earnings

by Sweta Killa

Sectors with positive earnings growth in Q4 include autos (86.3% earnings growth), construction (27.2%), basic materials (7.6%), medical (6.3%), and aerospace (4.4%).

Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

by Zacks Equity Research

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

Urmimala Biswas headshot

4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021

by Urmimala Biswas

Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.

AmerisourceBergen (ABC), WBA Ink Deal to Focus on Core Arms

by Zacks Equity Research

AmerisourceBergen (ABC) and Walgreens (WBA) enter into a key strategic deal to boost focus on core businesses, while extending their partnership.

NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health

by Zacks Equity Research

FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform

Why You Should Retain Veeva (VEEV) in Your Portfolio Now?

by Zacks Equity Research

Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.

LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay

by Zacks Equity Research

Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.

Integra (IART) Sells Unprofitable Arm to Focus on Core Business

by Zacks Equity Research

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

OPKO Health's (OPK) BioReference Starts Fan Testing Program

by Zacks Equity Research

OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.

Should Value Investors Buy McKesson (MCK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.

    MCK or CNMD: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    MCK vs. CNMD: Which Stock Is the Better Value Option?

    Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.

    Sandip Chakraborty headshot

    5 Stocks That Could Hit Several New Highs in 2021

    by Sandip Chakraborty

    Given the upbeat sentiments in the market, FedEx (FDX), Deere (DE), D.R. Horton (DHI), Fortescue (FSUGY) and Fiat Chrysler (FCAU) are expected to give good returns to investors in 2021.

    Here's Why You Should Hold on to Intuitive Surgical (ISRG) Now

    by Zacks Equity Research

    Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System. But weak operational performance is a woe.